Health Canada approves LEQEMBI (lecanemab), an antibody drug that can slow the cognitive decline in patients with early-stage Alzheimer’s disease. Eisai Ltd., a Japan-based pharmaceutical company, was the first to develop and manufacture the LEQEMBI drug, in joint partnership with Biogen, a US-based company and a major player in the biotechnology segment, and BioArctic, a […]
- Tags:
- Alzheimer’s care and support
- Alzheimer’s disease Canada
- Alzheimer’s drug approval
- Alzheimer’s medication Canada
- Alzheimer’s patient guide
- Alzheimer’s research news
- Alzheimer’s therapy access
- amyloid plaque
- APOE ε4
- ARIA monitoring
- brain health Canada
- dementia treatment update
- early Alzheimer’s treatment
- Eisai Biogen drug
- first disease-modifying therapy
- Health Canada approval
- Health Canada news release
- lecanemab
- LEQEMBI
- mild cognitive impairment